Loading

Research Article Open Access
Volume 1 | Issue 4 | DOI: https://doi.org/10.33696/Neurol.1.025

A Protocol for the Generation of Treatment-naïve Biopsy-derived Diffuse Intrinsic Pontine Glioma and Diffuse Midline Glioma Models

  • 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA
  • 2Molecular and Cellular Biology Graduate Program and Medical Scientist Training Program, University of Washington, Seattle, WA, USA
  • 3Department of Laboratories, Seattle Children’s Hospital, Seattle, WA, US
  • 4Department of Laboratory Medicine and Pathology, University of Washington School of Medicine, Seattle, WA, USA
  • 5Division of Neurosurgery, Department of Neurological Surgery, University of Washington, Seattle Children’s Hospital, Seattle, WA, USA
  • 6Division of Hematology/Oncology, Department of Pediatrics, Seattle Children’s Hospital, University of Washington, Seattle, WA, USA
+ Affiliations - Affiliations

Corresponding Author

Nicholas A. Vitanza, nicholas.vitanza@seattlechildrens.org

Received Date: October 10, 2020

Accepted Date: December 08, 2020

Abstract

Diffuse intrinsic pontine glioma (DIPG) is a universally fatal tumor of the brainstem, most commonly affecting young children. Due to its location, surgical resection is not achievable, but consideration of a biopsy has become standard practice at children’s hospitals with the appropriate neurosurgical expertise. While the decision to obtain a biopsy should be directed by the presence of atypical radiographic features that call the diagnosis of DIPG into question or the requirement of biopsy tissue for clinical trial enrollment, once this precious tissue is available its use for research should be considered. The majority of DIPG and diffuse midline glioma, H3 K27M-mutant (DMG) models are autopsy-derived or genetically-engineered, each of which has limitations for translational studies, so the use of biopsy tissue for laboratory model development provides an opportunity to create unique model systems. Here, we present a detailed laboratory protocol for the generation of treatment-naïve biopsy-derived DIPG/DMG models.

 

Author Information X